CRISCITIELLO, CARMEN
CRISCITIELLO, CARMEN
Dipartimento di Oncologia ed Emato-Oncologia
Cardiotoxicity of Agents Used in Patients With Breast Cancer
2024 P. Zagami, D. Trapani, E. Nicolò, C. Corti, C. Valenza, C. Criscitiello, G. Curigliano, L.A. Carey
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
2023 C. Corti, C. De Angelis, G. Bianchini, L. Malorni, M. Giuliano, E. Hamilton, R. Jeselsohn, K. Jhaveri, G. Curigliano, C. Criscitiello
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials
2023 G. Castellano, C. Corti, L. Boldrini, L. Gervaso, C. Criscitiello, G. Curigliano
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
2023 P. Trillo, J. Sandoval, D. Trapani, E. Nicolò, P. Zagami, F. Giugliano, P. Tarantino, G. Vivanet, L. Ascione, A. Friedlaender, A. Esposito, C. Criscitiello, G. Curigliano
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fuca, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Future potential targets of antibody-drug conjugates in breast cancer
2023 C. Corti, L. Boscolo Bielo, A.C. Schianca, B.T. Salimbeni, C. Criscitiello, G. Curigliano
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
2023 M. Ivanova, F.M. Porta, F. Giugliano, C. Frascarelli, E. Sajjadi, K. Venetis, G. Cursano, G. Mazzarol, E. GUERINI ROCCO, G. Curigliano, C. Criscitiello, N. Fusco
Trop-2 as an Actionable Biomarker in Breast Cancer
2023 G. Cursano, E. Frigo, E. Sajjadi, M. Ivanova, K. Venetis, E. Guerini-Rocco, C. Criscitiello, G. Curigliano, N. Fusco
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey
2023 N. Fusco, M. Ivanova, C. Frascarelli, C. Criscitiello, B. Cerbelli, M. Gemma Pignataro, A. Pernazza, E. Sajjadi, K. Venetis, G. Cursano, F. Pagni, C. Di Bella, M. Accardo, M. Amato, P. Amico, C. Bartoli, G. Bogina, L. Bortesi, R. Boldorini, S. Bruno, D. Cabibi, P. Caruana, E. Dainese, E. De Camilli, V. Dell’Anna, L. Duda, C. Emmanuele, G. Nicolò Fanelli, B. Fernandes, G. Ferrara, L. Gnetti, A. Gurrera, G. Leone, R. Lucci, C. Mancini, G. Marangi, M.G. Mastropasqua, L. Nibid, S. Orrù, M. Pastena, M. Peresi, L. Perracchio, A. Santoro, V. Vezzosi, C. Zambelli, V. Zuccalà, A. Rizzo, L. Costarelli, F. Pietribiasi, A. Santinelli, C. Scatena, G. Curigliano, E. Guerini-Rocco, M. Martini, P. Graziano, I. Castellano, G. D'Amati
Metaplastic breast cancer: an all-round multidisciplinary consensus
2023 G. Corso, C. Criscitiello, L. Nicosia, F. Pesapane, E. Vicini, F. Magnoni, A. Sibilio, C. Zanzottera, A.M. De Scalzi, S. Mannucci, M. Marabelli, M. Calvello, I. Feroce, P. Zagami, F.M. Porta, A. Toesca, P. Tarantino, E. Nicolò, G. Mazzarol, C. La Vecchia, B. Bonanni, M.C. Leonardi, P. Veronesi, N. Fusco
HER2-Low Breast Cancer: a New Subtype?
2023 C. Corti, F. Giugliano, E. Nicolò, P. Tarantino, C. Criscitiello, G. Curigliano
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care
2023 C. Corti, M. Cobanaj, E.C. Dee, C. Criscitiello, S.M. Tolaney, L.A. Celi, G. Curigliano
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
2023 F. Giugliano, A. Carnevale Schianca, C. Corti, M. Ivanova, N. Bianco, S. Dellapasqua, C. Criscitiello, N. Fusco, G. Curigliano, E. Munzone
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Evolution of low HER2 expression between early and advanced-stage breast cancer
2022 P. Tarantino, S. Gandini, E. Nicolo, P. Trillo, F. Giugliano, P. Zagami, G. Vivanet, F. Bellerba, D. Trapani, A. Marra, A. Esposito, C. Criscitiello, G. Viale, G. Curigliano
Targeting brain metastases in breast cancer
2022 C. Corti, G. Antonarelli, C. Criscitiello, N.U. Lin, L.A. Carey, J. Cortes, P. Poortmans, G. Curigliano
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano